



Subject Index to Volume 20

Volume 20

February	EMERGENCY CARDIOVASCULAR CARE, pages 1-180
May	CLINICAL HYPERTENSION, pages 181-340
August	ADVANCES IN ADULT CONGENITAL HEART DISEASE, pages 341-490
November	PERIPHERAL VASCULAR DISEASE, pages 491-662

Note: Page numbers of article titles are in **boldface** type

A

Abdominal aortic aneurysms, endovascular treatment of, **579-597**

early experience, 579-581

future perspectives, 586-587

indications for, 586

problems with current endograft devices, 583-586

endoleak, 583-585

morphological and structural changes, 585

secondary interventions after, 585-586

with Vanguard device, 581-583

open surgical treatment of, **563-578**

clinical suspicion, 564-565

definitions and diagnosis, 563-564

emerging strategies for small, 568-569

imaging surveillance *vs.* repair of, 566-567

open repair *vs.* endovascular repair, 567

postoperative complications, 573-575

referral to a high-volume center, 569

screening, 565

serendipitous discovery of, 565-566

techniques of, 569-573

juxtarenal, 572-573

retroperitoneal approach, 571-572

transabdominal approach, 569-571

transperitoneal *vs.* retroperitoneal repair, 567-568

Abdominal aortic disease, magnetic resonance angiography in diagnosis of, 507-508

Acute limb ischemia, approach to patient with, **513-520**

history, physical, and diagnosis, 513-514

pathophysiology, 514-515

therapy, 515-518

complications of, 518

economic impact of choice of, 518

endovascular, 516

lytic, in thrombosed bypass grafts, 517-518

percutaneous aspiration thrombectomy, 518

percutaneous mechanical thrombectomy, 518

surgical, 515-516

thrombolytic, 516-517

Adrenergic agonists, 64, 65

history of, 62

mechanism of action of, 63, 64

Adrenergic fibers, in autonomic nervous system, 62

Adrenergic inhibitors as antihypertensive

drugs, clinical pharmacology of, 267, 268, 270, 271

African-American Study of Kidney Disease, 308, 309

African-Americans, hypertension in, 307-309

treatment of, 307-309

Age, risk factor for critical limb ischemia, 536

Airway, alternative, 25

cuffed oropharyngeal, 25

emergency management of, **23-35**

esophageal obturator, 23, 24

laryngeal mask, 23, 24, 27, 28

Alagille syndrome, in tetralogy of Fallot, 387

Alcohol, and hypertension, 255, 256

- Aldosteronism, primary, as cause of secondary hypertension, 284
 diagnostic tests for, 284
 therapy for, 284
- Alpha agonists, central, as antihypertensive drugs, adverse effects of, 270
 clinical pharmacology of, 269, 270
- Alpha blockers as antihypertensive drugs, adverse effects of, 268, 269
 clinical pharmacology of, 268, 269
- American Heart Association Chain of Survival, 1
- Amiodarone, in cardiac arrest, 81, 83, 84
- Amputation, primary, due to critical limb ischemia, 543
- Anesthesia, for carotid endarterectomy, general *vs.* regional, 606-607
- Aneurysms, abdominal aortic. *See* Abdominal aortic aneurysms.
 atrial septum, relation of to cryptogenic stroke, 361, 362
 splanchnic artery, mesenteric disease due to, 616-620
- Angina, unstable, glycoprotein IIb/IIIa inhibitors in, 166-168
- Angiogenesis, therapeutic, 639-640
- Angiogenic growth factors, for intermittent claudication, 527
- Angiography, in diagnosis of peripheral arterial disease, magnetic resonance (MRA), 496, 498, 499, **501-512**, **553-555**
 x-ray digital subtraction, 498-499
- Angioplasty, balloon, and stenting for upper extremity arterial disease, 629-630
 infra-popliteal, for critical limb ischemia, 539
- Angiotensin receptor blockers as antihypertensive drugs, adverse effects of, 273, 274
 clinical pharmacology of, 273, 274
- Angiotensin-converting enzyme inhibitors, in acute coronary syndromes, 151
 in acute ischemic syndromes, 170, 171
 as antihypertensive drugs, adverse effects of, 272, 273
 clinical pharmacology of, 271-273
- Ankle-brachial index, for lower extremity arterial disease, 491, 492
- Antiarrhythmic drugs, in advanced cardiac life support, **79-87**
 animal studies of, 81
 basic principles of, 80
 basic science of, 80, 81
 clinical studies of, 81, 82
 history of, 79, 80
 state of the evidence regarding, 84
 unanswered questions about, 85
- Anticoagulation therapy, for carotid disease, 600
- Antidiuretic hormone, in normal blood pressure control, 197, 198
- Antihypertensive drugs, clinical pharmacology of, **265-280**
 in pregnancy, 306
- Antiplatelet therapy, for carotid disease, 599-600
 to reduce intermittent claudication, 525
- Aorta, abdominal aortic aneurysms. *See* Abdominal aortic aneurysms.
- Aortic arch, magnetic resonance angiography of, 508-511
- Aortofemoral bypass, in patients with critical limb ischemia, 540
- Apnea, sleep, as cause of secondary hypertension, diagnostic tests for, 284
 therapy for, 284
- Arginine, L-, for intermittent claudication, 527
- Arms, arterial disease in. *See* Upper extremities, arterial disease of.
- Arrhythmia(s), atrial, and hemodynamics, 356-358
 atrial flutter and, 358
 atrioventricular synchrony and, 357, 358
 in congenital heart disease, **457-465**
 electrophysiology and RF-ablation in, 359, 360
 inappropriate heart rate and, 357
 pacemaker therapy for, 359
 pharmacologic therapy for, 358, 359
 role of surgery in treatment of, 360, 361
 treatment of, 358-361
 and ventricular rhythm irregularity, 358
 cardiac, and sudden death, hypertensive, 237, 238
 prevention of, 238
- Arterial disease, abdominal aortic aneurysms, endovascular treatment, **579-597**

- surgical treatment, **563-578**
 - carotid stenosis, medical and surgical aspects, **599-609**
 - percutaneous treatment, **589-597**
 - central and peripheral, hypertensive, 238, 239
 - diagnostic implications of, 238
 - epidemiology of, 238
 - pathophysiology and treatment of, 238
 - prevention of, 239
 - prognosis of, 238, 239
 - intermittent claudication, **521-534**
 - limb ischemia, acute, **513-520**
 - chronic critical, **535-545**
 - lower extremity, diagnostic aspects, **491-500**
 - magnetic resonance angiographic techniques for diagnosis of, **501-512**
 - mesenteric occlusive and aneurysmal, **611-621**
 - molecular approaches to atherosclerosis treatment, **633-643**
 - renal artery disease, atherosclerotic, **547-562**
 - upper extremity, **623-631**
- Arteries, great, transposition of. *See* Transposition of the great arteries.
- Arteriography, for diagnosis of renal vascular disease, 551-552
 - at time of cardiac catheterization, 551-552
- Artifacts, in magnetic resonance angiography, 511-512
- Aspiration thrombectomy, percutaneous, for acute limb ischemia, 518
- Aspirin, in early immediate treatment of acute coronary syndromes, 165, 166
- Asymptomatic Carotid Atherosclerosis Study, 602
- Atherosclerosis. *See also* Arterial disease., molecular approaches for treatment of, **633-643**
 - bio-artificial graft conduits, 639
 - bypass vein graft atherosclerosis, 635-637
 - gene-based interventions, potential for, 633-635
 - hyperlipidemia, 640-641
 - postangioplasty restenosis, 637-639
 - therapeutic angiogenesis, 639-640
- Atherosclerotic renal artery disease, **547-562**
- Atria, hemodynamic function of, and Fontan procedure, 356
 - and postoperative pattern of atrial filling, 353
 - in specific conditions, 353-356
 - in structurally normal heart, 351-353
 - in tetralogy of Fallot, 353-355
 - in transposition of the great arteries after Mustard or Senning procedure, 355
 - role of in congenital heart disease, **351-366**
 - in structurally normal heart, booster pump function of, 352, 353
 - conduit function of, 352
 - hemodynamic function of, 351-353
 - reservoir function of, 351, 352
- Atrial fibrillation, in congenital heart disease, 458
 - hypertensive, 237, 238
- Atrial flutter, and atrial arrhythmias, 358
 - in congenital heart disease, 458
- Atrioventricular synchrony, atrial arrhythmias and, 357, 358
- Autonomic dysfunction, evaluation of patients with, 291-293
 - biochemical assessment in, 293
 - noninvasive tests for, 292
 - response to meals in, 292, 293
- hypertension in, 294-296
 - blood volume and, 296
 - contribution of baroreflex failure to, 294, 295
 - inappropriate natriuresis as consequence of, 295
 - incidence and severity of, 294
 - long-term consequences of, 295, 296
 - multiple system atrophy and residual sympathetic tone driving, 296, 297
 - pathophysiology of, 296-298
 - treatment of, 298-300
 - vasodilators for, 299, 300
- orthostatic hypotension in, and associated hypertension, 291-302
 - with blunted tachycardia, 291, 292
 - differential diagnosis of, 291
- pure autonomic failure (PAF) syndromes in, 293, 294
 - pathophysiology of hypertension in, 297, 298
- AV-synchrony. *See* Atrioventricular synchrony.

B

- Balloon angioplasty, for carotid stenosis, 589
- and stent implantation for upper extremity arterial disease, 629-630

Beck, Claude, 13

- Beta blockers as antihypertensive drugs, adverse effects of, 268
clinical pharmacology of, 267, 268
- Bio-artificial grafts, molecular approach to designing, 639
- Biofeedback, and hypertension, 259
- b-Blockers, in acute coronary syndromes, 150
in acute ischernic syndromes, 170
- Blood pressure, elevation of. *See* Hypertension.
- Blood pressure control, normal, 195-198
antidiuretic hormone activity in, 197, 198
feedback mechanisms in, 195-197
intermediate-acting mechanisms of, 197, 198
late-acting mechanisms of, 198
physiology of, 195-198
rapid-acting mechanisms of, 195, 197
renin-angiotensin systems in, 197, 198
- Blood pressure measurement, ambulatory, 217
monitors for, 216
aneroid devices for, 212
auscultatory gap in, 214
auscultatory method of, 208
technical sources of error with, 214, 215
in the clinic, 217
clinical importance of, 218
combined use of clinic, home, and ambulatory monitoring of, 218
cuff-inflation hypertension and, 210
devices for, 210-217
validation of, 210, 211
in different situations, 217
during exercise, 220
effects of body position on, 209, 210
effects of cuff size on, 210
effects of posture on, 209
in the elderly, 219
electronic monitors for self-monitoring of, 215-217
finger cuff method of, 208, 209, 215, 216
Hawksley Random Zero device for, 212
in infants and children, 219, 303
locations for, 207, 208
mercury sphygmomanometers for, 211
oscillometric technique of, 208
by the patient, 217
potential sources of error in, 209, 210
in pregnant women, 219
principles and techniques in, 207-223
rate of cuff inflation and deflation in, 213
in special populations and circumstances, 219, 220
ultrasound techniques of, 208
use of stethoscope bell in, 213
white coat effect in, 212, 213
wrist monitors for, 215
- Brain, as target organ in hypertension, 225-247
- Bretylium, in cardiac arrest, 80-82
- Bright's disease, hypertension and, 282
- Bypass procedures, in patients with critical limb ischemia, 540-541
- Bypass vein graft atherosclerosis, prevention of, molecular approach to, 635-637
-
- ## C
- C-reactive protein, role of, in peripheral arterial disease, 525-526
- Calcium, and hypertension, 255
- Calcium channel antagonists, in acute ischemic syndromes, 171
- Calcium channel blockers as antihypertensive drugs, adverse effects of, 275
clinical pharmacology of, 274, 275
- Captopril renography, in diagnosis of renal artery stenosis, 555
- Cardiac arrest, pressor drugs in treatment of, 61-78
- Cardiac catheterization, in assessment of right ventricular function, 345
renal arteriography at time of, 551-552
- Cardiac chamber enlargement and wall hypertrophy, hypertensive, diagnostic evaluation of, 230
epidemiology of, 228, 229
pathophysiology of, 229, 230
prevention of, 231, 232
prognosis of, 230, 231
treatment of, 230
- Cardiopulmonary resuscitation (CPR), active compression-decompression, 40-44
practical aspects of, 51-54
rescuer fatigue in, 51
basic life support, 1-12
blood flow during, abdominal pump mechanism of, 38
cardiac pump mechanism of, 38, 42

- mathematical model of, 39
 - modern physiology of, 38-44
 - thoracic pump mechanism of, 38, 42, 43
 - breathing techniques in, bag mask device in, 6-8
 - cricoid pressure and, 8
 - mouth-to-barrier device, 4-6
 - mouth-to-mask, 5-7
 - mouth-to-mouth, **3, 4**
 - mouth-to-nose, **4**
 - use of face shield in, 5
 - by one rescuer, 10, 11
 - by two rescuers, 11
 - circulatory adjuncts of, **37-59**
 - warnings about general use of, 56
 - four-phase, 49-53
 - interposed abdominal compression, 45-49
 - combining of with active compression-decompression cardiopulmonary resuscitation, 55, 56
 - coordination of chest and abdominal compressions in, 54, 55
 - hand position and compression technique in, 54
 - practical aspects of, 54-56
 - training individuals to do, 55
 - newer methods of, circulatory adjuncts as, **37-59**
 - performance of, 2-11
 - quality of, during rescue efforts, 1, 2
 - steps in, airway opening as, 2, 3
 - assessment of responsiveness and activation of response system as, 2
 - breathing as, 3-8
 - checking for signs of circulation as, 8, 9
 - chest compressions as, 9, 10
 - use of pressor drugs in, 74, 75
- Cardio Pump, 51**
- Cardiovascular disease, mortality from, 187**
- Cardiovascular Health Branch of Centers for Disease Control, 324, 325**
- Cardioverter-defibrillator, internal, defibrillation in patients with, 16**
- Carnitine, L-, for intermittent claudication, 527**
- Carotid artery disease, extra-cranial, magnetic resonance angiography of, 508-511**
- Carotid Artery Stenosis with Asymptomatic Narrowing, Operation Versus Aspirin study, 602-603**
- Carotid endarterectomy, for carotid stenosis, 601-607**
 - acute internal carotid artery occlusion, 605-606
 - after a fixed stroke, 605
 - after stroke in evolution/crescendo TIA, 605
 - in asymptomatic disease, 601-603
 - concomitant carotid and coronary disease, 606
 - predictors of perioperative risk, 601
 - restenosis after, 606
 - in symptomatic disease, 603-605
 - technical controversies in, 606-607
 - anesthesia, general *vs.* regional, 606-607
 - intraoperative shunting, 607
 - primary repair *vs.* patch closure, 607
- Carotid restenosis, after endarterectomy, 606**
- Carotid stenosis, diagnosis, 600-601**
 - medical and surgical aspects, **599-609**
 - anticoagulation, 600
 - antiplatelet therapy, 599-600
 - carotid endarterectomy, 601-607
 - lipid-lowering therapy, 600
 - percutaneous treatment for, **589-587**
 - balloon angioplasty, 589
 - stenting, 589-592
 - adjuvant pharmacological therapy, 593
 - emboli protection during, 592-593
 - surgery *vs.*, 593-594
- Catheterization, cardiac, renal arteriography at time of, 551-552**
- Celiac artery aneurysms, 618**
- Chain of Survival, of American Heart Association, 1**
- Chest pain, acute ischemic, algorithm for, 160, 161**
 - clinical classification of, 142
 - low-risk patients with, clinical recognition of, 118
 - management of, 118
 - traditional management of, limitations of, 117, 118
- Chest pain centers, accelerated diagnostic protocols in, 122**
 - for acute ischemic syndromes, **117-136**
 - cardiac serum markers in, 125, 126

- Chest pain centers (*continued*)
- clinical guidelines, critical pathways, algorithms, and protocols in, 123, 124
 - utility of, 124, 125
 - coronary angiography in, 132
 - cost-effectiveness of, 123
 - development of, 119
 - early noninvasive cardiac testing in, 126-132
 - echocardiography in, 128-130
 - electron beam computed tomography in, 131, 132
 - exercise testing in, 126-128
 - initial patient triage in, 120-122
 - management of low-risk patients with negative findings in, 132
 - myocardial scintigraphy in, 130, 131
 - new electrocardiographic methods in, 125
 - predictive instruments in, 123
 - rationale for, 118, 119
 - staffing of, 119, 120
- Cholinergic fibers, in autonomic nervous system, 62
- Chronic critical limb ischemia. *See* Critical limb ischemia.
- Cigarette smoking, and hypertension, 259
- Cilostazol, for intermittent claudication, 526
- Circulatory adjuncts, in cardiopulmonary resuscitation, 37-59
- warnings about general use of, 56
- Claudication, intermittent. *See* Intermittent claudication.
- Clinics, nurse-managed, in prevention and treatment of hypertension, 329, 330
- Clonidine as antihypertensive drug, clinical pharmacology of, 269, 270
- Colic artery aneurysms, 619
- Combined alpha and beta blockers as antihypertensive drugs, adverse effects of, 269
- clinical pharmacology of, 269
- Combitube, Esophageal-Tracheal, 24, 26, 27
- Community health systems partnerships, for hypertension prevention, with barbershops, beauty salons, and fire stations, 328
- with faith-based organizations, 327, 328
 - with pharmacists, 328
 - with work sites, 326, 327
- Compliance, patient, and control of hypertension, 188
- Congenital heart disease, and genetic heterogeneity, 387
- atrial arrhythmias in. assessment of, 458, 459
 - atrial defibrillators for, 461, 462
 - catheter ablation for, 461
 - drug therapy for, 460, 461
 - pacing therapy for, 461
 - prevention of, 463, 464
 - surgery for, 462, 463
 - therapy for, 459-463
 - types of, 457, 458
 - atrial fibrillation in, 458
 - atrial ventricular nodal reentrant tachycardia in, 458
 - atrioventricular reentrant tachycardia
 - secondary to a bypass tract or Wolff-Parkinson-White syndrome, 457, 458
 - catheter and surgical ablation in, 467-484
 - classic atrial flutter in, 458
 - counseling patients on risk of recurrence of, 389
 - definition of, 383
 - difficulties in recognizing genetic causes of, 385-387
 - focal atrial tachycardia in, 458
 - genetics of, 383-392
 - genomics and, 389, 390
 - identifying possible genetic causes of, 384, 385
 - incisional atrial reentrant tachycardia in, 458
 - molecular genetic studies and, 391
 - origins of in fetal life, 367-382
 - advances in genetics and, 367, 368
 - possibility of prevention of, 390
 - pulmonary arterial hypertension in, 439-455
 - reduced penetrance in, 387
 - role of animal models of, 390, 391
 - role of atria in, 351-366
 - and significance of identifying disease-causing genes, 388
 - single gene inheritance and, 388, 389
 - tachyarrhythmias in, 468
 - novel technology for treatment of, 476, 477
 - surgical treatment of, 469-471
 - three-dimensional electrical reconstruction in, 477, 478
 - three-dimensional electroanatomical reconstruction in, 476, 477
 - three-dimensional navigational reconstruction in, 477, 479
 - transcatheter radiofrequency current ablation for, 471-473
 - variable expressivity and NKX2.5 mutations in, 387, 388

- Congestive heart failure, due to renal artery stenosis, 551
 - revascularization for control of, 560
- Coronary artery disease, concomitant carotid artery disease and, 606
- hypertensive, 236, 237
 - diagnostic implications of, 236
 - epidemiology of, 236
 - pathophysiology of, 236
 - prevention of, 237
 - treatment and prognosis of, 236, 237
- mortality from, 187, 188
- Coronary syndromes, acute, 159
 - adjunctive therapy for, 150-152
 - algorithm for, 162
 - angiotensin-converting enzyme inhibition in, 151
 - β -blockers in, 150
 - cardiogenic shock as, treatment for, 144-146
 - clinical symptoms of, 141, 142
 - coronary or myocardial reflow in, 139, 140
 - coronary patency in, strategies for establishing or maintaining, 137-157
 - magnesium in, 152
 - nitrates in, 151, 152
 - open artery and survival in, 139
 - pathophysiology of, 137-139
 - percutaneous coronary intervention for, versus fibrinolysis, 146, 148
 - in perspective, 153, 154
 - prehospital fibrinolysis for, 144
 - primary stenting and facilitated percutaneous coronary intervention and fibrinolysis in, 149, 150
 - reperfusion era in, 137-157
 - risk stratification of, 143, 144
 - biochemical cardiac markers in, 143
 - and the elderly, 148, 149
 - initial, 140-143
 - ST-segment in, 142, 143
 - ST-segment elevation myocardial infarction as, heparin in, 150
 - treatment of, 144
 - treatment of, aspirin in, 165, 166
 - early immediate, 164-166
 - glycoprotein IIb/IIIa inhibitors in, 166
 - morphine in, 165
 - nitroglycerin in, 164, 165
 - oxygen in, 164
 - subsequent, 166-171
 - treatment strategies for, 144-153
 - unstable angina non-ST-segment elevation myocardial infarction as, 152, 153

- Critical limb ischemia, chronic, 535-545
 - economic costs of, 535
 - failed grafts as cause of, 541-542
 - graft surveillance, 542
 - management of, 542
 - failing graft, management of, 542-543
 - incidence and prevalence, 535
 - laboratory testing, vascular, 537
 - long-term fate of patient with, 535
 - medical management, 537-538
 - presenting features and physical examination, 536-537
 - primary amputation, 543
 - revascularization approaches, 538-539
 - risk factors for, 535-536
 - surgical management, 539-540
 - of outflow disease, 540-541
- Cushing's syndrome, as cause of secondary hypertension, 284, 285
 - diagnostic tests for, 285
 - therapy for, 285

D

Defibrillation, 13-21

- early, principle of, 16, 17
 - effect of water on, 16
 - electrode size and position in, 15
 - external, automated, 15, 16
 - on airlines, 17, 18
 - in casinos, 18
 - in police cars, 17
 - history of, 13, 14
 - in the hospital, 19
 - in patients with pacemaker/internal cardioverter defibrillator, 16
 - pediatric, 19
 - presence of nitroglycerin paste or other transdermal medication in, 16
 - public access, 17-19
 - trial of, 18, 19
 - special circumstances during, 16
 - transthoracic impedance in, 14, 15
 - waveform technology in, 14
- Diabetes mellitus, hypertension in, 313-315
 - active drug treatment trials for, 314, 315
 - and drug studies that included normotensive people, 315
 - Diabetes mellitus (Continued)
 - epidemiology of, 313, 314
 - therapeutic recommendations for, 315
 - risk factor for critical limb ischemia, 537

Dietary Approaches to Stop Hypertension (DASH) trial, 251-253

Digital subtraction angiography, x-ray, for lower extremity arterial disease diagnostics, 498-499

Diuretics as antihypertensive drugs, clinical pharmacology of, 265, 266
adverse effects of, 265
special categories of, clinical pharmacology of, 265

Doppler analysis, for lower extremity arterial disease diagnosis, 493
of upper extremity arterial disease, 627

Down syndrome, in tetralogy of Fallot, 387

Duplex sonography, arterial, for diagnosis of arterial disease, lower extremity, 494-495
upper extremity, 627
for renal artery stenosis diagnosis, 552-553

Dysbetalipoproteinemia, familial, type III, role of, in peripheral arterial disease, 525

E

Ebstein's anomaly, of tricuspid valve, **429-437**
clinical presentation and diagnostic evaluation of, 431-434
pathophysiology of, 430, 431
pregnancy and, 434
prognosis of, 435, 436
tachycardia associated with, 468, 469
therapy for, 434, 435

Echo-Doppler measurements, in assessment of right ventricular function, 346, 347

Embolism, causing acute limb ischemia, 514
paradoxical, and patent foramen ovale, 362
protection against, during percutaneous carotid intervention, 592-593
of superior mesenteric artery, acute intestinal occlusion due to, 614-616

Emergency care, cardiopulmonary resuscitation in, 2-11

Emergency medical services (EMS) systems, in acute ischemic syndromes, 105-107
access to, 105, 106
dispatch of, 106
hospital triage and EMS planning in, 107
levels and types of service by, 106, 107

Endarterectomy, carotid. *See* Carotid endarterectomy.
for upper extremity arterial disease, 629-630

Endovascular treatment, of abdominal aortic aneurysms, **579-597**
early experience, 579-581
future perspectives, 586-587
indications for, 586
problems with current endograft devices, 583-586
endoleak, 583-585
morphological and structural changes, 585
secondary interventions after, 585-586
with Vanguard device, 581-583
for acute limb ischemia, 516
for critical limb ischemia, 538-539
for intermittent claudication, 529-531

Epinephrine, 62, **64**, 65
alternatives to, 70-74
in cardiac arrest, dosage of, 67-70
current recommendations for, 74
and neurologic outcome, 66
pharmacology of, 65, 66
toxicity of, 66, 67
and ventricular fibrillation, 66

European Carotid Surgery Trial, 603-604

Exercise, as therapy for intermittent claudication, 526

Extremities, arterial disease of, lower, diagnostic aspects of, **491-500**
upper, **623-631**

F

Failure, of graft. *See* Graft failure.

Fetal heart development, 368-381
aortic and pulmonary trunk development in, 376-378
abnormal, 376, 377
genetics of, 377, 378
normal, 376
atrioventricular valve development in, 375, 376
abnormal, 375
genetics of, 375, 376
normal, 375
development of the aorta and its branches in, 378-381
abnormal, 379-381
genetics of, 381
normal, 378, 379
from fertilization to primitive heart tube, abnormal, 368
genetics of, 368, 369
normal, 368

- from looping to wedging, 370-372
 - abnormal, 371
 - genetics of, 371, 372
 - normal, 370, 371
- from primitive heart tube through looping, 369, 370
 - abnormal, 369, 370
 - genetics of, 370
 - normal, 369
- septation of the atria in, 372-375
 - abnormal, 373, 374
 - genetics of, 374, 375
 - normal, 372, 373
- Fetus, origins of congenital heart disease in, 367-382
- Fibrillation, atrial. *See* Atrial fibrillation
- Finger pressures, for diagnosis of upper extremity arterial disease, 626
- Fish oil, and hypertension, 255
- Fontan procedure, postoperative hemodynamic function in, 356
- Foot care, in critical limb ischemia, 537
- Foramen ovale, patent. *See* Patent foramen ovale.

G

- Gadolinium-based magnetic resonance angiography, 503-505
 - dosage, 503-504
 - paramagnetic contrast agents for, 503
 - parameters for optimal, 504-505
 - spoiled gradient echo imaging, 504
- Gastric artery aneurysms, 618-619
- Gastroduodenal artery aneurysms, 619-620
- Gastroepiploic artery aneurysms, 618-619
- Gastrointestinal complications, after surgery for abdominal aortic aneurysms, 574
- Gene-based interventions, potential, for treatment of atherosclerosis, 633-635
- Genetics, advances in, and understanding of the origins of congenital heart disease, 367, 368
- Glomerulonephritis, hypertension and, 282
- Glycemic control, to reduce intermittent claudication, 524

- Graft failure, as cause of critical limb ischemia, 541-543
 - early failure, 541
 - graft surveillance, 542
 - late failure, 541-542
 - management of patient with failed graft, 542
 - management of patient with failing graft, 542-543
- Graft infection, after surgery for abdominal aortic aneurysms, 574
- Graft surveillance, in critical limb ischemia, 542
 - for lower extremity arterial disease diagnosis, 495-496
- Grafts, bypass, atherosclerosis of, prevention of, molecular approach to, 635-637
 - prosthetic, molecular approach to designing bioartificial graft conduits, 639
- Guanethidine as antihypertensive drug, clinical pharmacology of, 270, 271

H

- Heart, fetal development of. *See* Fetal heart development.
 - as target organ in hypertension, 225-247
 - asymptomatic left ventricular systolic dysfunction from, 234, 235
 - cardiac arrhythmias and sudden death from, 237, 238
 - cardiac chamber enlargement and wall hypertrophy from, 228-232
 - chronic heart failure from, 235, 236
 - coronary heart disease from, 236, 237
 - left ventricular diastolic dysfunction from, 232, 233
- Heart failure, chronic, hypertensive, diagnostic implications of, 235
 - epidemiology of, 235
 - treatment and prognosis of, 235
 - treatment of, 235, 236
- Heath-Edwards classification of pulmonary vascular changes in congenital heart disease, 441, 442
- Hemorrhage, after surgery for abdominal aortic aneurysms, 573
- Heparin, in ST-segment elevation myocardial infarction, 150, 151
- Hepatic artery aneurysms, 617-618

- Homocysteine, role of, in peripheral arterial disease, 525
- Hydralazine as antihypertensive drug, clinical pharmacology of, 275, 276
- Hyperlipidemia, correction of, to reduce intermittent claudication, 523
experimental genetic treatment of, 640-641
- Hypertension, in African-Americans, 307-309
alcohol consumption and, 255, 256
background information on, 321
bad news about, 182, 184
calcium and, 255
in children, 303-305
blood pressure measurement in, 303
diagnostic evaluation of, 304, 305
etiology of, 303, 304
treatment of, 305
cigarette smoking and, 259
clinical care and, 329, 330
in nurse-managed clinics, 329, 330
community outreach for, 328, 329
control of. *See also* Blood pressure control.
in Latin American countries, 189
patient compliance and, 188
to reduce intermittent claudication, 523-524
control rates of, worldwide, 182
cuff-inflation, 210
Cushing's syndrome as cause of, 284, 285
diagnostic tests for, 285
therapy for, 285
detection and control of, population and policy implications of, 187-194
in diabetes mellitus, 313-315
and dietary factors other than sodium intake, 254, 255
education about, community health system partnerships for, 326-328
effective strategies for, 321-332
fish oil and, 255
global burden of, 181-185
recommendations for reducing, 184
global risk assessment in, 191
good news about, 181, 182
heart, kidney and brain as target organs in, 225-247
clinical presentations of damage to, 228-241
mechanisms of damage of, 227, 228
risk stratification and, 225, 226
spectrum of damage to, 225-228
in kidney disease, 309-311
lifetime risk of, 192
obesity and, 258, 259
in orthostatic hypotension and autonomic dysfunction, 291-302
pathogenesis, and clinical physiology of, 195-206
in renal artery stenosis, 547-548, 550
pathophysiologic states of, 198-203
pheochromocytoma as cause of, 285
diagnostic tests for, 285
therapy for, 285
physical activity and, 256, 257
posttransplantation, 311-313
potassium and, 255
in pregnancy, 305-307
prevalence in the general population, 187
prevalence of, in United States, 181
prevention and control of. *See also* Blood pressure control.
community health systems partnerships for, 326-328
community outreach for, 328, 329
nondrug interventions in, 249-263
public health approaches to, 321-324
salt intake and, 249-254
primary, pathogenesis of, 199-203
renin-angiotensin system and, 201, 202
role of genes in, 199, 200
role of the environment in, 200
role of the kidney in, 202, 203
sympathetic nervous system and, 200, 201
vascular remodeling, hypertrophy, and increased peripheral resistance and, 202
primary aldosteronism as cause of, 284
diagnostic tests for, 284
therapy for, 284
pulmonary arterial. *See* Pulmonary arterial hypertension.
relative risk of, 192
renal artery stenosis as cause of, 282, 283
diagnostic tests for, 283
therapy for, 283
renoparenchymal disease as cause of, 283, 284
diagnostic tests for, 284
therapy for, 284
resistant, 281, 282
causes of, 281
definition of, 281
treatment of, 281, 282
risk stratification in, and global risk assessment, growing importance of, 189-193

- implications of, 192, 193
 - problems of, 190-192
 - secondary, 282-285
 - causes of, 282
 - definition of, 282
 - sleep apnea as cause of, 284
 - diagnostic tests for, 284
 - therapy for, 284
 - in special populations, **303-319**
 - state-run programs for detection, treatment, and control of, 324, 326
 - stress and, 259
 - supine, in autonomic failure,
 - nonpharmacologic treatment of, 298
 - pharmacologic treatment of, 298-300
 - unifying pathway for development of, 203
 - websites for information about, 183, 184
 - "white coat," 212, 213
 - yoga, meditation, and acupuncture in, 259, 260
- Hypertensive crises, 285-287**
- causes of, 285
 - definition of, 285
 - treatment of, 285-287
- Hypotension, orthostatic, with autonomic dysfunction, hypertension in, 291-302*
-
- I**
- Ileal artery aneurysms, 619
- Imaging, diagnostic, for peripheral arterial disease, in lower extremities, 491-500*
- magnetic resonance angiography techniques, **501-512**
- Infection, of graft, after surgery for abdominal aortic aneurysms, 574**
- Infrageniculate bypass, in patients with critical limb ischemia, 540-541*
- Intermittent claudication, in peripheral arterial disease, 521-534**
- diagnosis, 521-522
 - management, 522-531
 - exercise therapy for, 526
 - novel risk factors in, 525-526
 - pharmacologic therapy for, 526-527
 - risk factor modification, 522-525
 - surgical approaches, 527-531
 - presentation, 521
- Internal carotid artery occlusion, acute, 605-606**
- Intestinal ischemia. See Mesenteric arterial disease.**

- Intubation, tracheal, 23, 25, 28-31**
- carbon dioxide detectors in, 31
 - confirming tube placement following, 30, 31
 - esophageal detector device in, 31
 - indications for, 29
- Ischemia, intestinal, chronic mesenteric, secondary to arteriosclerosis, 611-614**
- due to acute embolic occlusive disease, 614-616
 - low-flow, 616
- limb, acute. See Acute limb ischemia.**
- after surgery for abdominal aortic aneurysms, 574-575
 - chronic critical. *See Critical limb ischemia.*
 - upper extremity, conditions and risks for, 625
- Ischemic syndromes, acute, adjunctive therapy for, 159-175**
- chest pain center concept in, **117-136**
 - chest pain in, algorithm for, 160, 161
 - delay in therapy for, 104, 105
 - disposition of, 112, 113
 - early response to, **103-116**
 - emergency medical services (EMS) systems
 - issues in, 105-107
 - access to, 105, 106
 - dispatch of, 106
 - hospital triage and EMS planning in, 107
 - levels and types of service by, 106, 107
 - initial management of, in the emergency room, 110, 111
 - out-of-hospital electrocardiography in, 107, 108
 - patient education about, 104, 105
 - pre-hospital thrombolysis in, 108-110
 - risk stratification in, 111, 112

J

- Jejunal artery aneurysms, 619
- Juxtarenal abdominal aortic aneurysms, 572-573

K

- Kidney, role of in primary hypertension, 202, 203**
- as target organ in hypertension, 225-247
 - Kidney disease. *See also Renal failure.*
 - hypertension in, 309-311
 - and kidney function changes with treatment, 311

Kidney (*continued*)

- therapeutic caveats in, 311
- treatment of, 310, 311

L

Laboratory evaluation, of upper extremity ischemia, 627, 628

L-Arginine, for intermittent claudication, 527

L-Carnitine, for intermittent claudication, 527

Left ventricle, interaction of with right ventricle, 343, 344

Left ventricular diastolic dysfunction, hypertensive, 232, 233

- diagnostic implications of, 233
- epidemiology of, 232
- pathophysiology of, 232, 233
- prevention of, 233
- treatment and prognosis of, 233

Left ventricular outflow, anatomy and topography of, 419

Left ventricular systolic dysfunction, asymptomatic, hypertensive, 234, 235

- diagnostic implications of, 234
- epidemiology of, 234
- pathophysiology of, 234
- prevention of, 234, 235
- treatment and prognosis of, 234

Legs, arterial disease in. *See* Lower extremities. ischemia of. *See* Acute limb ischemia and Critical limb ischemia. pain in. *See* Intermittent claudication.

Lidocaine, in cardiac arrest, 80, 82

Life support, cardiac, antiarrhythmic drugs in, 79-87

Limb ischemia, acute. *See* Acute limb ischemia. after surgery for abdominal aortic aneurysms, 574-575 chronic critical. *See* Critical limb ischemia.

Lipid-lowering therapy, for carotid disease, 600

Lipoprotein(a), role of, in peripheral arterial disease, 525

Lower extremities, arterial disease of, diagnostic aspects of, 491-500

Lown, Bernard, 14

Ludwig, Karl, 13

Lytic therapy, in thrombosed bypass grafts, for acute limb ischemia, 517-518

M

Magnesium, in acute coronary syndromes, 152 in acute ischemic syndromes, 171 as antiarrhythmic agent, 81, 83

Magnetic resonance angiography (MRA), for diagnosis of arterial disease, 496, 498, 499, 501-512

- extra-cranial carotid and arch disease, 508-511
- mesenteric-portal disease, 508
- peripheral arterial disease, 506-507
- renal artery stenosis, 553-555
- renovascular and abdominal aortic disease, 507-508
- gadolinium-based, 503-505
- time-of-flight techniques, 505-506

Magnetic resonance imaging (MRI), in assessment of right ventricular function, 347, 348

- field gradients, Fourier transforms, and fast MRI techniques, 502-503
- fundamental physics of, 501-502
- safety checks and artifacts, 511-512

McWilliam, John, 13

Mechanical thrombectomy, percutaneous, for acute limb ischemia, 518

Medical therapy, for atherosclerotic renal disease, 555-556

- for carotid disease, 599-600
- adjuvant, with percutaneous treatment, 593
- for chronic critical limb ischemia, 537-538
- for intermittent claudication, 526-527
- for upper extremity arterial disease, 629

Mercury sphygmomanometers, 211, 212

Mesenteric arterial disease, magnetic resonance angiography in diagnosis of, 508 occlusive and aneurysmal, 611-621

- mesenteric ischemia, 611-616
- acute embolic occlusive disease, 614-615
- low-flow nonocclusive ischemia, 616
- splanchnic artery aneurysms, 616-620

Methyldopa as antihypertensive drug, clinical pharmacology of, 269

Minnesota Heart Health Program, 323, 325

Minoxidil as antihypertensive drug, clinical pharmacology of, 276, 277

- Molecular biology, in treatment of atherosclerosis, **633-643**
 bio-artificial graft conduits, 639
 bypass vein graft atherosclerosis, 635-637
 gene-based interventions, potential for, 633-635
 hyperlipidemia, 640-641
 postangioplasty restenosis, 637-639
 therapeutic angiogenesis, 639-640
- Morphine, in early immediate treatment of acute coronary syndromes, 165
- Mustard procedure for transposition of the great arteries, 405-411
 cardiac rhythm issues after, 410
 drug therapies for, 411
 functional status and exercise physiology after, 405-408
 late arterial switch after, 411
 postoperative hemodynamic function after, 355
 right ventricular function after, 408
 assessment of, 408, 409
 right ventricular hypertrophy and function after, 409
 tricuspid valve function after, 410
- Myocardial dysfunction, postresuscitation, **89-101**
 clinical evidence for, 93-95
 experimental evidence for, 89-93
 mechanism of action of, 95, 96
 potential treatments for, 96-100
- Myocardial infarction, ST-segment elevation,
 heparin in, 150, 151
 treatment of, 144
 unfractionated heparin in, 169, 170
 unstable angina non-ST-segment elevation, 152, 153
 glycoprotein IIb/IIIa inhibitors in, 166-168
 low-molecular-weight heparin in, 168, 169
-
- N**
- National Health and Nutrition Examination Surveys (NHANES), 182
 hypertension treatment and control rates in, 188, 189
- National Heart, Lung, and Blood Institute (NHLBI), hypertension prevention programs of, community-based demonstration projects in, 322, 325

- National High Blood Pressure Education Program (NHBPEP), 321, 322
- Nephropathy, ischemic, pathophysiology of, in renal artery stenosis, 548
- Nervous system, autonomic, 62, 63
- Nitrates, in acute coronary syndromes, 151, 152
- Nitroglycerin, in early immediate treatment of acute coronary syndromes, 164, 165
- North American Symptomatic Carotid Endarterectomy Trials, 603-604

O

- Obesity, and hypertension, 258, 259
- Occlusive disease, mesenteric arterial, **611-621**
 acute embolic, 614-616
 chronic arteriosclerotic, 611-614
- Orthostatic hypotension and autonomic dysfunction, hypertension in, 291-302
 relevance of to essential hypertension, 300, 301
 treatment of, 300
- Outflow disease, in patients with critical limb ischemia, surgical management of, 540-541
- Oxygen, in early immediate treatment of acute coronary syndromes, 164

P

- Pacemaker(s), defibrillation in patients with, 16
- Pain, in legs. *See* Intermittent claudication.
- Pain management, in critical limb ischemia, 537
- Pancreatic artery aneurysms, 619-620
- Pancreaticoduodenal artery aneurysms, 619-620
- Patch closure, *vs.* primary repair, in carotid endarterectomy, 607
- Patent foramen ovale, catheter closure of, 362
 paradoxical embolism and, 362
 relation of to cryptogenic stroke, 361, 362
 stroke prophylaxis in, 361, 362
- Pawtucket Heart Health Program, 323-325
- Penetrance, reduced, in congenital heart disease, 387

- Pentoxifylline, for intermittent claudication, 526-527
- Percutaneous thrombectomy, for acute limb ischemia, aspiration, 518
mechanical, 518
- Percutaneous transluminal angioplasty, for critical limb ischemia, 538-539
aorto-iliac, and stenting, 538-539
femoro-popliteal, and stenting, 539
for intermittent claudication, 529-531
aorto-iliac, and stenting, 529-530
intrapopliteal, 531
- Peripheral arterial disease, acute limb ischemia due to, **513-520**
intermittent claudication in, **521-534**
lower extremity, diagnosis of, **491-500**
- Pharmacologic therapy. *See* Medical therapy.
- Phenylephrine, 70, 71
- Pheochromocytoma, as cause of secondary hypertension, 285
diagnostic tests for, 285
therapy for, 285
- Physical activity, and hypertension, 256, 257
- Potassium, and hypertension, 255
- Preeclampsia, 305-307
management of, 307
pathophysiology of, 306, 307
- Pregnancy, hypertension in, 305-307
antihypertensive drugs during, 306
chronic, management of, 306
classification of, 305, 306
preeclampsia and, 306, 307
normal blood pressure in, 305
- Pressor drugs, in cardiopulmonary resuscitation, 74, 75
efficacy of, 64
history of, 62
mechanism of action of, 63, 64
in treatment of cardiac arrest, **61-78**
- Preventive Health and Health Services Block Grant, for hypertension screening programs, 324
- Procainamide, in cardiac arrest, 80, 81, 83
- Profundoplasty, adjunctive, in patients with critical limb ischemia, 540
- Prostaglandins, for intermittent claudication, 527
- Prosthetic grafts, molecular approach to designing, 639
- Pulmonary arterial hypertension, in congenital heart disease, **439-455**
directed medical therapies for, 446-452
endothelin inhibitors for, 449
endothelium in, 441, 443
evolving therapies for, 449-452
genetics and, 445, 446
Heath-Edwards classification of pulmonary vascular changes in, 441, 442
pathologic changes in, 440, 441
prognosis of, 440
risk factors for, 439, 440
treatment of, 446
vasoconstriction abnormalities in, 443-445
vasodilators for, 446-449
- Pulmonary edema, "flash," due to renal artery stenosis, 551
revascularization for control of, 560
- Pulmonary insufficiency, after surgery for abdominal aortic aneurysms, 573
- Pulse volume recordings, for arterial disease
diagnosis, lower extremity, 493
upper extremity, 626-627
-
- R**
- Radiography, for diagnosis of upper extremity arterial disease, 627
- Radionuclide studies, in assessment of right ventricular function, 346
- Rastelli operation for transposition of the great arteries with ventricular septal defect and pulmonary stenosis, 413
- Raynaud's phenomenon, in upper extremity arterial disease, 623, 624
- Renal artery stenosis, atherosclerotic, **547-562**
clinical features and presentation, 548-551
diagnosis of, 551-555
arteriography, 551
captopril renography, 555
duplex ultrasonography, 552-553
magnetic resonance angiography, 507-508, 553-555
renal arteriography a time of cardiac catheterization, 551-552
renal vein renin measurements, 555

- management of, 555-560
 - for control of congestive heart failure or flash pulmonary edema, 560
 - indications for revascularization, 555
 - medical therapy, 555-556
 - patient selection for interventions, 559-560
 - percutaneous transluminal angiography, 556
 - stents, 556-557
 - surgical revascularization, 557-559
- pathophysiology of, 547-548
- as cause of secondary hypertension, 282, 283
 - diagnostic tests for, 283
 - therapy for, 283
- Renal failure. *See also* Kidney disease.
 - after surgery for abdominal aortic aneurysms, 573-574
- end-stage, hypertensive, 240, 241
 - diagnostic evaluation of, 241
 - epidemiology of, 240
 - pathophysiology of, 240, 241
 - prevention of, 241
 - treatment of, 241
- Renin measurements, renal vein, in diagnosis of renal artery stenosis, 555
- Renin-angiotensin system, in normal blood pressure control, 197, 198
 - primary hypertension and, 201, 202
- Renoparenchymal disease, as cause of secondary hypertension, 283, 284
 - diagnostic tests for, 284
 - therapy for, 284
- ResQ-Pump, 51
- Restenosis, carotid, after endarterectomy, 606
 - postangioplasty, molecular approach to, 637-639
- Revascularization, for peripheral arterial disease. *See* Endovascular treatment and Surgery.
- Right ventricle, interaction of with left ventricle, 343, 344
 - physiology of, 341-343
- Right ventricular function, **341-349**
 - assessment of, 345-348
 - cardiac catheterization in, 345
 - echo-Doppler measurements in, 346, 347
 - magnetic resonance imaging in, 347, 348
 - radionuclide studies in, 346
 - and cardiopulmonary interactions, 344, 345

S

- Safety checks, in magnetic resonance angiography, 511-512
- Salt intake, and hypertension, 249-254
 - animal studies of, 250
 - clinical trials related to, 251-253
 - cohort studies of, 251
 - community intervention trials on, 253, 254
 - current policies on, 253, 254
 - overview of research on, 250-253
 - population surveys of, 250, 251
- Segmental limb pressures, for diagnosis of arterial disease, lower extremity, 493
 - upper extremity, 625-626
- Senning procedure for transposition of the great arteries, 405-411
 - cardiac rhythm issues after, 410
 - catheter interventions for baffle complications after, 410, 411
 - drug therapies for, 411
 - functional status and exercise physiology after, 405-408
 - late arterial switch after, 411
 - postoperative hemodynamic function after, 355
 - right ventricular function after, 408
 - assessment of, 408, 409
 - right ventricular hypertrophy and function after, 409
 - tricuspid valve function after, 410
- Shock, cardiogenic, treatment for, 144-146
- Shunting, intraoperative, during carotid endarterectomy, 607
- Shy-Drager syndrome, 291
- Sleep apnea, as cause of secondary hypertension, diagnostic tests for, 284
 - therapy for, 284
- Smoking, and hypertension, 259
 - risk factor for critical limb ischemia, 537
- Smoking cessation, to reduce intermittent claudication, 522-523
- Somatization syndrome, 132
- Sonography, arterial duplex, for lower extremity arterial disease diagnosis, 494-495
 - for renal artery stenosis diagnosis, 552-553
- Sphygmomanometer, mercury, 211, 212
- Splanchnic artery aneurysms, 616-620

Splenic artery aneurysms, 616-617

Stanford Five-City Project of hypertension prevention, 323, 325

Stanford Three-Community Study of hypertension prevention, 322, 323, 325

Stenosis, subaortic. *See* Subaortic stenosis.

Stenting, balloon angioplasty and, for upper extremity arterial disease, 629-630

for carotid artery stenosis, 589-592

renal artery, 556-557

for treatment of intermittent claudication, 529-531

Stress, hypertension and, 259

Stroke, cryptogenic, relation of patent foramen ovale and atrial septum aneurysm to, 361, 362

in evolution/crescendo TIA, carotid endarterectomy after, 605

hypertensive, 239, 240

diagnostic evaluation of, 239

epidemiology of, 239

pathophysiology of, 239

prevention of, 240

prognosis of, 240

treatment of, 239

ischemic, common causes of, 599, 600

fixed, carotid endarterectomy after, 605

mortality from, 187, 188

as indicator of prevalence of hypertension, 187, 188

racial and ethnic factors in, 187, 188

prevention of, from carotid disease, 599, 600

"Stroke belt," 188

Subaortic stenosis, aortoventriculoplasty for, 423

at-risk substrates and treatment strategies for, 419-427

atrioventricular septal defects and, 420, 421

creating an outlet septum ventricular septal defect for, 422

discrete, in a "normal heart," 419, 420

fibrous ring resection for, 422

in long intraventricular tunnels, 424

myectomy for, 422

operations for, 422-424

patching the anterior leaflet of the left atrioventricular valve for, 422, 423

Shone's complex and, 421, 422

in the single ventricle, 422

surgical management strategy for, 424-426

Toronto adult experience and, 425, 426

treatment controversy in, 426

ventricular septal defect and, 420

Superior mesenteric artery aneurysms, 618

Surgery, for abdominal aortic aneurysms, 563-578

for acute limb ischemia, 515-516

for critical limb ischemia, 539-541

for revascularization in intermittent claudication, 527-529

aorto-iliac disease, 528

infra-inguinal disease, 528-529

for revascularization in renal artery stenosis, 557-560

for upper extremity arterial disease, 629-630

Surveillance, graft, for lower extremity arterial disease diagnosis, 495-496

in critical limb ischemia, 542

Sympathetic nervous system, primary hypertension and, 200, 201

T

Tachyarrhythmias, atrial ventricular nodal reentrant tachycardia, in congenital heart disease, 458

atrioventricular reentrant, secondary to a bypass tract or Wolff-Parkinson-White syndrome, 457, 458

in congenital heart disease, role of surgery and radiofrequency current ablation for, 477, 480

focal atrial, in congenital heart disease, 458

incisional atrial reentrant, in congenital heart disease, 458

transcatheter radiofrequency current ablation for, in acquired substrates, 472, 473

in congenital substrates, 471, 472

validation of success of, 473-476

types of, 468, 469

Tetralogy of Fallot, anatomy of, 393

genetic counseling for patients with, 399, 400

genetic heterogeneity and, 387

late problems in, 393-402

postoperative hemodynamic function in, 353-355

surgical repair of, 393-395

aneurysmal dilation of the right ventricular outflow tract after, 396

management of, 399

prevention of, 401

aortic regurgitation with or without aortic root dilation after, 396

- aortic root dilation after, management of, 399
 prevention of, 401
electrical problems after, 396-398
endocarditis after, 396
 prevention of, 401
heart block after, 396
 management of, 400
late problems after, 395-398
 management of, 399, 400
 prevention of, 400, 401
left ventricular dysfunction after, 396
 management of, 399
 prevention of, 401
mechanical problems after, 395, 396
 management of, 399
pregnancy after, 398-400
premature ventricular contraction after, 397
 management of, 400
pulmonary regurgitation after, management of, 399
 prevention of, 400
residual right ventricular outflow tract obstruction after, 396
 management of, 399
residual ventricular septal defect after, 396
 management of, 399
restrictive right ventricle after, 395
 management of, 399
 prevention of, 400, 401
right ventricular dilation after, 395
 management of, 399
 prevention of, 400
sudden cardiac death after, 398, 400
 prevention of, 401
supraventricular arrhythmia after, 396, 397
 management of, 400
 prevention of, 401
ventricular tachycardia after, 397
 management of, 400
 prevention of, 401
- Thrombectomy, percutaneous, for acute limb ischemia, aspiration, 518
 mechanical, 518
 surgical, 515-516
- Thrombolytic therapy, for acute limb ischemia, 516-517
- Thrombosis in situ, causing acute limb ischemia, 514
- Time-of-flight magnetic resonance angiography, 505-506, 507
- Transplantation, hypertension following, 311-313
 causes of, 312
 epidemiology of, 311, 312
 and mechanism of calcineurin hypertension/ cardiovascular toxicity, 312
 treatment of, 312, 313
- Transposition complexes in the adult, **403-418**
 complete transposition as, 403-405
 congenitally corrected transposition of the great arteries as, 413-415
 transposition with ventricular septal defect and pulmonary stenosis as, 413
- Transposition of the great arteries, complete, 403-405
 arterial switch operation for, 411-413
 early mortality in, 412
 exercise after, 413
 mid- to long-term followup of, 412
 surgical and nonsurgical interventions after, 412, 413
 atrial baffle operations for, 405-411
 natural history of, 405
 congenitally corrected, 413-415
 associated lesions in, 414
 "double switch" operation for, 415
 functional status in, 414
 natural history and surgical results of, 414
 right ventricular dysfunction in, 414
 tricuspid valve regurgitation in, 414, 415
 postoperative hemodynamic function in, following Mustard or Senning procedure, 355
 with ventricular septal defect and pulmonary stenosis, 413
- Treadmill exercise arterial studies, for lower extremity arterial disease diagnosis, 493-494
- Tricuspid valve, anatomy of, 429, 430
 Ebstein's anomaly of, **429-437**
- Trisomy 21, in tetralogy of Fallot, 387
-
- U**
- Ulcers, in critical limb ischemia, 536, 537
 care of, 537, 538
- Ultrasonography, arterial duplex, for lower extremity arterial disease diagnosis, 494-495
 for renal artery stenosis diagnosis, 552-553

- Upper extremities, arterial disease of, **623-631**
 approach to treatment, 629-630
 diagnosis, 623-627
 pathophysiology, 627-629

V

- Valve(s), tricuspid. *See* Tricuspid valve.
- Vanguard device, for endovascular treatment of abdominal aortic aneurysms, 581-582
- Vascular testing, for lower extremity arterial disease, current diagnostic algorithm, 499
 invasive, 498-499
 x-ray digital subtraction angiography, 498-499
 noninvasive, 491-498
 ankle-brachial index, 491, 492
 arterial duplex sonography, 494-495
 Doppler waveform analysis, 493
 graft surveillance, 495-496
 magnetic resonance angiography, 496, 498
 segmental limb pressures and pulse volume recordings, 493
 treadmill exercise arterial studies, 493-494
- Vasodilators, direct, as antihypertensive drugs, adverse effects of, 276, 277
 clinical pharmacology of, 275-277
- Vasopeptidase inhibitors as antihypertensive drugs, clinical pharmacology of, 277
- Vasopressin, 71-74
 current recommendations for, 74
 in laboratory models, 72
 route of administration of, 72, 73
 in treatment of cardiac arrest, 73, 74
- Ventilation, bag-valve mask, 24, 25
 management of, **23-35**
 mouth-to-mask, 24
- Ventilators, automatic transport, 31, 32
- Ventricular fibrillation, epinephrine and, 66
- Veterans Affairs Cooperative Asymptomatic Trial, 602
- Veterans Affairs Cooperative Symptomatic Trial, 603, 604-605

W

- White coat effect in blood pressure measurement, 212, 213
- Wolff-Parkinson-White syndrome, atrioventricular reentrant tachycardia
 secondary to, 457, 458
 tachycardia associated with, 468, 469

X

- X-ray digital subtraction angiography, for lower extremity arterial disease diagnostics, 498-499

